HOME > REGULATORY
REGULATORY
- Apply GDP to Cash-and-Carry Dealers Too: MHLW Panel Members
April 24, 2017
- MHLW Committee Backs Approval of Mundipharma’s PTCL Med Pralatrexate
April 24, 2017
- Commerce Secretary Ross Made No Specific Demand on Drug Pricing: Shiozaki
April 24, 2017
- Negative Opinions Exist for Use of Cost Effective Assessments in Drug Listing: MHLW Official
April 24, 2017
- Sakigake Fast-Track Designation Given to Aducanumab, 4 Other Products
April 24, 2017
- MHLW Panel OKs 2-Year Extension of Reexamination Period for E Keppra due to Development of Dosage for Children Younger than 4
April 24, 2017
- MHLW to Examine Bayer Issue from Pharmaceutical Law Viewpoint without Prejudgment: Bureau Chief
April 21, 2017
- Lawmakers Whispering Thresholds for Off-Year-Revision Products; Top 30% in Discrepancy Rates Floated
April 21, 2017
- MOF Puts June-End Generic Share at Around 65%, Just Shy of Mid-Year 70% Target
April 21, 2017
- MOF Calls for Scrapping Price Maintenance Premium
April 21, 2017
- MHLW Cautions on Incidences of Multiple Vertebral Body Fractures after Discontinuation of Pralia Treatment
April 21, 2017
- MHLW Re-Cautions Use of Sleep/Anxiolytic/Epilepsy Agents Containing 44 APIs
April 19, 2017
- Optimal Use Guidelines Issued for Opdivo Use in RCC, Hodgkin’s Lymphoma
April 19, 2017
- New MHLW Panel Starts Discussions on Proper Drug Use Guidelines for Elderly; Final Report Expected by End of FY2018
April 19, 2017
- Amicus Takes Over GSK’s Orphan Status for Migalastat for Fabry’s Disease
April 18, 2017
- Review of 14-Day Prescription Limit Up for Chuikyo Discussion Again
April 18, 2017
- AMED to Launch Portal Site to Promote Use of Biobanks as Part of Effort to Support Genomic Medicine
April 18, 2017
- With Clinical Research Law Enacted, MHLW Eyes New Panel to Discuss Requirements for “Specified Clinical Research”: R&D Division Head
April 17, 2017
- Japan, South Korea to Hold 2nd Joint Regulation Symposium in May
April 17, 2017
- Clinical Research Law Promulgated
April 17, 2017
ページ
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
